Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 6/20 | 0.43 |
| ▸ | FLT3 | P36888 | 6/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808729 | 0.85 | PTGS2 (0.38) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL2808733 | 0.85 | PTGS2 (0.38) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL2782296 | 0.81 | PTGS2 (0.44) | PTGS2JAK1JAK3JAK2GRM4 | |
| SCHEMBL185694 | 0.81 | AKR1C3 (0.47) | KITFLT3EPHX2DHODH | |
| SCHEMBL27870363 | 0.80 | PTGS2 (0.42) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL2784614 | 0.78 | JAK1 (0.43) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL246040 | 0.78 | PTGS2 (0.41) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL27870381 | 0.77 | PTGS2 (0.38) | PTGS2KITFLT3JAK1JAK3 | |
| SCHEMBL185903 | 0.76 | KIT (0.44) | KITFLT3ARMAPK10DHODH | |
| SCHEMBL185795 | 0.75 | JAK1 (0.39) | PTGS2KITFLT3JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | PTGS2 3027/4885KIT 989/4885FLT3 632/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | PTGS2 3027/4885KIT 989/4885FLT3 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.